Fecal immunochemical testing may reduce colorectal cancer mortality
the ONA take:
Population-based fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in colorectal cancer mortality despite a short follow-up time, a new study published online in the journal Cancer has shown.
For the prospective cohort study, over 1.1 million Taiwanese people between the ages of 50 and 69 years underwent fecal immunochemical testing screening between 2004 and 2009. Researchers then compared colorectal cancer-specific mortality for a screened group with an unscreened group.
Results showed that fecal immunochemical testing screening reduced colorectal cancer-specific mortality by 62% with a maximum follow-up of 6 years. After adjustments for a self-selection bias, researchers found that screening reduced cancer-specific morality by 10%.
Although the findings show a significant reduction, this study has had a short follow-up time. Researchers plan to continue following-up this large cohort to assess the long-term effect of fecal immunochemical testing screening.
Fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in mortality.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|